BMS: Reblozyl label supplement approved; GLORY CAR-T trial and BMS-986485 Phase 1 posted
Bristol-Myers Squibb's week includes a Reblozyl labeling approval, a new glofitamab/liso-cel lymphoma trial, and a first-in-human study of BMS-986485.
The week brought a label update, a new lymphoma trial registration, and a healthy-volunteer Phase 1 study tied to Bristol-Myers Squibb, alongside an older terminated head and neck trial already on record.
- REBLOZYL (luspatercept-aamt), Celgene Corp's BLA761136, received a standard-review labeling supplement (SUPPL 17) with approval status recorded as of 2026-10-20 and an approval letter dated 2026-10-21.
- "Phase 2 Study of Glofitamab and Gemcitabine and Oxaliplatin (Glofit-GemOx) Bridging to Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas" (NCT07711483, GLORY) is recruiting. The trial is led by Massachusetts General Hospital with Bristol-Myers Squibb as a collaborator.1 It is expected that about 52 people will take part in this research study.1
- A Phase 1 first-in-human study of Bristol-Myers Squibb's BMS-986485 (NCT07887763) is not yet recruiting. The study will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of orally administered BMS-986485 in healthy adult participants, with a conditional open-label part to assess relative bioavailability of alternate formulations.2 Enrollment is estimated at 50 participants.2
- "Window-of-opportunity Trial of Nivolumab and BMS-986205 in Patients With Squamous Cell Carcinoma of the Head and Neck (HNSCC)" (NCT03854032) remains listed as terminated due to toxicity concerns by the Sponsor3, with Thomas Jefferson University as lead sponsor and Bristol-Myers Squibb as collaborator; results were first posted 2026-10-19.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.